Dyrk1 inhibition improves Alzheimer's disease-like pathology

Caterina Branca, Darren M. Shaw, Ramona Belfiore, Vijay Gokhale, Arthur Y. Shaw, Christopher Foley, Breland Smith, Christopher Hulme, Travis Dunckley, Bessie Meechoovet, Antonella Caccamo, Salvatore - Oddo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

There is an urgent need for the development of new therapeutic strategies for Alzheimer's disease (AD). The dual-specificity tyrosine phosphorylation-regulated kinase-1A (Dyrk1a) is a protein kinase that phosphorylates the amyloid precursor protein (APP) and tau and thus represents a link between two key proteins involved in AD pathogenesis. Furthermore, Dyrk1a is upregulated in postmortem human brains, and high levels of Dyrk1a are associated with mental retardation. Here, we sought to determine the effects of Dyrk1 inhibition on AD-like pathology developed by 3xTg-AD mice, a widely used animal model of AD. We dosed 10-month-old 3xTg-AD and nontransgenic (NonTg) mice with a Dyrk1 inhibitor (Dyrk1-inh) or vehicle for eight weeks. During the last three weeks of treatment, we tested the mice in a battery of behavioral tests. The brains were then analyzed for the pathological markers of AD. We found that chronic Dyrk1 inhibition reversed cognitive deficits in 3xTg-AD mice. These effects were associated with a reduction in amyloid-β (Aβ) and tau pathology. Mechanistically, Dyrk1 inhibition reduced APP and insoluble tau phosphorylation. The reduction in APP phosphorylation increased its turnover and decreased Aβ levels. These results suggest that targeting Dyrk1 could represent a new viable therapeutic approach for AD.

Original languageEnglish (US)
Pages (from-to)1146-1154
Number of pages9
JournalAging Cell
Volume16
Issue number5
DOIs
StatePublished - Oct 1 2017

Fingerprint

Alzheimer Disease
Pathology
Amyloid beta-Protein Precursor
Phosphorylation
Inhibition (Psychology)
Brain
Amyloid
Intellectual Disability
Protein Kinases
Animal Models
Therapeutics
Dyrk kinase
Proteins

Keywords

  • 3xTg-AD
  • AD
  • Alzheimer's disease
  • amyloid beta
  • plaques
  • tangles

ASJC Scopus subject areas

  • Aging
  • Cell Biology

Cite this

Branca, C., Shaw, D. M., Belfiore, R., Gokhale, V., Shaw, A. Y., Foley, C., ... Oddo, S. . (2017). Dyrk1 inhibition improves Alzheimer's disease-like pathology. Aging Cell, 16(5), 1146-1154. https://doi.org/10.1111/acel.12648

Dyrk1 inhibition improves Alzheimer's disease-like pathology. / Branca, Caterina; Shaw, Darren M.; Belfiore, Ramona; Gokhale, Vijay; Shaw, Arthur Y.; Foley, Christopher; Smith, Breland; Hulme, Christopher; Dunckley, Travis; Meechoovet, Bessie; Caccamo, Antonella; Oddo, Salvatore -.

In: Aging Cell, Vol. 16, No. 5, 01.10.2017, p. 1146-1154.

Research output: Contribution to journalArticle

Branca, C, Shaw, DM, Belfiore, R, Gokhale, V, Shaw, AY, Foley, C, Smith, B, Hulme, C, Dunckley, T, Meechoovet, B, Caccamo, A & Oddo, S 2017, 'Dyrk1 inhibition improves Alzheimer's disease-like pathology', Aging Cell, vol. 16, no. 5, pp. 1146-1154. https://doi.org/10.1111/acel.12648
Branca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C et al. Dyrk1 inhibition improves Alzheimer's disease-like pathology. Aging Cell. 2017 Oct 1;16(5):1146-1154. https://doi.org/10.1111/acel.12648
Branca, Caterina ; Shaw, Darren M. ; Belfiore, Ramona ; Gokhale, Vijay ; Shaw, Arthur Y. ; Foley, Christopher ; Smith, Breland ; Hulme, Christopher ; Dunckley, Travis ; Meechoovet, Bessie ; Caccamo, Antonella ; Oddo, Salvatore -. / Dyrk1 inhibition improves Alzheimer's disease-like pathology. In: Aging Cell. 2017 ; Vol. 16, No. 5. pp. 1146-1154.
@article{d3a097a9166f4cc890c25708f74b9539,
title = "Dyrk1 inhibition improves Alzheimer's disease-like pathology",
abstract = "There is an urgent need for the development of new therapeutic strategies for Alzheimer's disease (AD). The dual-specificity tyrosine phosphorylation-regulated kinase-1A (Dyrk1a) is a protein kinase that phosphorylates the amyloid precursor protein (APP) and tau and thus represents a link between two key proteins involved in AD pathogenesis. Furthermore, Dyrk1a is upregulated in postmortem human brains, and high levels of Dyrk1a are associated with mental retardation. Here, we sought to determine the effects of Dyrk1 inhibition on AD-like pathology developed by 3xTg-AD mice, a widely used animal model of AD. We dosed 10-month-old 3xTg-AD and nontransgenic (NonTg) mice with a Dyrk1 inhibitor (Dyrk1-inh) or vehicle for eight weeks. During the last three weeks of treatment, we tested the mice in a battery of behavioral tests. The brains were then analyzed for the pathological markers of AD. We found that chronic Dyrk1 inhibition reversed cognitive deficits in 3xTg-AD mice. These effects were associated with a reduction in amyloid-β (Aβ) and tau pathology. Mechanistically, Dyrk1 inhibition reduced APP and insoluble tau phosphorylation. The reduction in APP phosphorylation increased its turnover and decreased Aβ levels. These results suggest that targeting Dyrk1 could represent a new viable therapeutic approach for AD.",
keywords = "3xTg-AD, AD, Alzheimer's disease, amyloid beta, plaques, tangles",
author = "Caterina Branca and Shaw, {Darren M.} and Ramona Belfiore and Vijay Gokhale and Shaw, {Arthur Y.} and Christopher Foley and Breland Smith and Christopher Hulme and Travis Dunckley and Bessie Meechoovet and Antonella Caccamo and Oddo, {Salvatore -}",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/acel.12648",
language = "English (US)",
volume = "16",
pages = "1146--1154",
journal = "Aging Cell",
issn = "1474-9718",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Dyrk1 inhibition improves Alzheimer's disease-like pathology

AU - Branca, Caterina

AU - Shaw, Darren M.

AU - Belfiore, Ramona

AU - Gokhale, Vijay

AU - Shaw, Arthur Y.

AU - Foley, Christopher

AU - Smith, Breland

AU - Hulme, Christopher

AU - Dunckley, Travis

AU - Meechoovet, Bessie

AU - Caccamo, Antonella

AU - Oddo, Salvatore -

PY - 2017/10/1

Y1 - 2017/10/1

N2 - There is an urgent need for the development of new therapeutic strategies for Alzheimer's disease (AD). The dual-specificity tyrosine phosphorylation-regulated kinase-1A (Dyrk1a) is a protein kinase that phosphorylates the amyloid precursor protein (APP) and tau and thus represents a link between two key proteins involved in AD pathogenesis. Furthermore, Dyrk1a is upregulated in postmortem human brains, and high levels of Dyrk1a are associated with mental retardation. Here, we sought to determine the effects of Dyrk1 inhibition on AD-like pathology developed by 3xTg-AD mice, a widely used animal model of AD. We dosed 10-month-old 3xTg-AD and nontransgenic (NonTg) mice with a Dyrk1 inhibitor (Dyrk1-inh) or vehicle for eight weeks. During the last three weeks of treatment, we tested the mice in a battery of behavioral tests. The brains were then analyzed for the pathological markers of AD. We found that chronic Dyrk1 inhibition reversed cognitive deficits in 3xTg-AD mice. These effects were associated with a reduction in amyloid-β (Aβ) and tau pathology. Mechanistically, Dyrk1 inhibition reduced APP and insoluble tau phosphorylation. The reduction in APP phosphorylation increased its turnover and decreased Aβ levels. These results suggest that targeting Dyrk1 could represent a new viable therapeutic approach for AD.

AB - There is an urgent need for the development of new therapeutic strategies for Alzheimer's disease (AD). The dual-specificity tyrosine phosphorylation-regulated kinase-1A (Dyrk1a) is a protein kinase that phosphorylates the amyloid precursor protein (APP) and tau and thus represents a link between two key proteins involved in AD pathogenesis. Furthermore, Dyrk1a is upregulated in postmortem human brains, and high levels of Dyrk1a are associated with mental retardation. Here, we sought to determine the effects of Dyrk1 inhibition on AD-like pathology developed by 3xTg-AD mice, a widely used animal model of AD. We dosed 10-month-old 3xTg-AD and nontransgenic (NonTg) mice with a Dyrk1 inhibitor (Dyrk1-inh) or vehicle for eight weeks. During the last three weeks of treatment, we tested the mice in a battery of behavioral tests. The brains were then analyzed for the pathological markers of AD. We found that chronic Dyrk1 inhibition reversed cognitive deficits in 3xTg-AD mice. These effects were associated with a reduction in amyloid-β (Aβ) and tau pathology. Mechanistically, Dyrk1 inhibition reduced APP and insoluble tau phosphorylation. The reduction in APP phosphorylation increased its turnover and decreased Aβ levels. These results suggest that targeting Dyrk1 could represent a new viable therapeutic approach for AD.

KW - 3xTg-AD

KW - AD

KW - Alzheimer's disease

KW - amyloid beta

KW - plaques

KW - tangles

UR - http://www.scopus.com/inward/record.url?scp=85026758625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026758625&partnerID=8YFLogxK

U2 - 10.1111/acel.12648

DO - 10.1111/acel.12648

M3 - Article

C2 - 28779511

AN - SCOPUS:85026758625

VL - 16

SP - 1146

EP - 1154

JO - Aging Cell

JF - Aging Cell

SN - 1474-9718

IS - 5

ER -